Worrying Statements by Uğur Şahin

With the pandemic entering our lives, the whole world began to wait for the day it would end. About the family of viruses that cause the ongoing pandemic, although it is largely under control today. BioNTech’s co-founder Ugur Sahin He made some rather unflattering statements.

Speaking to the Financial Times, Şahin mentioned the resistance of the virus to the vaccine in his statements. Besides whether a new vaccine will be needed Making statements about the issue, Şahin said that there is no need for such a thing this year, but that the situation will be different in the future.

The formula of the COVID-19 vaccine may vary:

Stating that the virus in question will continue to mutate, Şahin said that with these mutations, the vaccine revealed immunity will weaken told. He made the following statements about whether a new vaccine is needed:

“By the middle of next year, the Covid-19 vaccine The formula will need to be changed It looks like the virus is mutating. There was no need to develop a new vaccine this year. But by the middle of next year it is much more it will be a different situation”

Also mentioning the Delta variant, Şahin said, Delta variant more contagious, but enough to reduce the effectiveness of existing vaccines. is not different told. Stating that the third dose of supportive vaccines may work in controlling the delta variant and other variants, Şahin said, on the other hand, that new mutations may emerge and that the effect of the vaccines you can weaken also affected.

Speaking about the evolution of the virus while talking about its mutations, Şahin said the following:

“The virus will remain will adapt even more. We do not anticipate that the next generation of viruses that will change will be more manageable than they are now. This is an ongoing evolution and evolution has just begun”

Finally, Şahin, for those who are vaccinated about their 2022 plans your third dose to those who do not have access to the vaccine. vaccine will be provided told. In response to calls to share the patent for the vaccine, he responded by saying that sharing patents would put quality control at risk.